Composition and kit for detecting methylation of human plasma EYA4 gene and LCAT gene

By combining EYA4 and LCAT gene methylation detection methods with real-time PCR technology, a kit for gastric cancer was developed, which solved the problems of sensitivity and specificity in the early diagnosis of gastric cancer and achieved non-invasive and efficient early screening and diagnosis of gastric cancer.

CN121272045APending Publication Date: 2026-01-06LIXIN NUOKANG (SHANDONG) BIOMEDICAL TECHNOLOGY CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410882626.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-03
Publication Date
2026-01-06

AI Technical Summary

Technical Problem

Existing technologies are insufficient for effective and non-invasive early diagnosis of gastric cancer, especially for patients with poor adherence to gastroscopy, as there is a lack of highly sensitive and specific detection methods.

Method used

Using methylation detection methods for the EYA4 and LCAT genes, and by designing specific primers and probes, combined with quantitative real-time PCR technology, a kit for gastric cancer was developed. Plasma DNA was used for detection, establishing a highly sensitive and specific early screening and diagnosis system for gastric cancer.

Benefits of technology

It achieves an early detection sensitivity of 96% and a specificity of 96% for gastric cancer. It is non-invasive and simple, and is suitable for early screening and diagnosis of gastric cancer.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN121272045A_ABST
    Figure CN121272045A_ABST
Patent Text Reader

Abstract

The invention discloses a composition for detecting methylation of an EYA4 gene and an LCAT gene in human plasma, which can be used for realizing early screening and early diagnosis of gastric cancer through detection of plasma DNA (Deoxyribose Nucleic Acid). Meanwhile, the invention also provides a kit for methylation of EYA4 and LCAT genes, the sensitivity of the kit for detection of gastric cancer patients reaches 91.6%, and the specificity of the kit is 94.6%.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of biotechnology, and in particular relates to a composition for detecting methylation of the EYA4 gene and LCAT gene in human plasma. Background Technology

[0002] Stomach cancer has the highest incidence rate among malignant tumors of the digestive tract worldwide, affecting more than 300 million people. Stomach cancer is the third most common cancer in my country, accounting for almost half of all stomach cancers worldwide. If it is not detected and treated early, it may develop into mid-to-late stage stomach cancer, which is life-threatening. Data shows that the cure rate for early-stage stomach cancer can reach more than 90%, while the cure rate for advanced-stage stomach cancer is only 30%. Therefore, effective detection of early-stage stomach cancer is the key to the prevention and control of stomach cancer in my country. Summary of the Invention

[0003] The purpose of this invention is to provide a composition and kit for detecting methylation of the EYA4 and LCAT genes in human plasma, for the auxiliary diagnosis of gastric cancer in patients with poor adherence to gastroscopy. The detection targets CpG sites in the promoter regions of the EYA4 and LCAT genes, offering high accuracy, convenient sampling, and minimal invasiveness.

[0004] To achieve the above objectives, one technical solution adopted by the present invention is: a composition for detecting methylation of the EYA4 gene and LCAT gene in human plasma, wherein the composition comprises the EYA4 gene and the LCAT gene.

[0005] Furthermore, the primer sequence for the EYA4 gene is SEQ ID No: 1; and the primer sequence for the LCAT gene is SEQ ID No: 2.

[0006] Furthermore, the probe sequence of the EYA4 gene is SEQ ID No: 4; and the probe sequence of the LCAT gene is SEQ ID No: 5.

[0007] To elaborate further, the internal reference for quantitative real-time PCR detection is the ACTB gene, the primer sequence for the ACTB gene is SEQ ID No: 3, and the probe primer sequence is SEQ ID No: 6.

[0008] A kit for detecting early gastric cancer includes EYA4 gene primers and probes, LCAT gene primers and probes, ACTB internal reference gene primers and probes, and PCR amplification enzyme reaction solution.

[0009] The beneficial effects of this invention are:

[0010] This invention provides a combined detection kit for EYA4 and LCAT gene dimethylation, which can be used for early screening and diagnosis of gastric cancer through plasma DNA detection; specifically:

[0011] First, we designed primers and probes to establish a methylation amplification system targeting CpG-rich regions of the EYA4 and LCAT genes, and tested the sensitivity and specificity of the PCR system for gastric cancer using FFPE samples.

[0012] Then, the performance of the kit was validated through extensive testing of clinical plasma samples, including comprehensive testing of benign gastric lesion samples and other gastrointestinal tumor samples.

[0013] This invention develops a novel dual-gene methylation detection kit, which achieves a sensitivity of 96% and a specificity of 96% for gastric cancer detection by detecting the EYA4 and LCAT genes. The method is simple and non-invasive, enabling early screening and diagnosis of gastric cancer. Attached Figure Description

[0014] Figure 1 This is the ROC curve of the PCR system for detecting the EYA4 gene and LCAT gene in the sample according to the present invention. Detailed Implementation

[0015] The preferred embodiments of the present invention will now be described in detail with reference to the accompanying drawings, so that the advantages and features of the present invention can be more easily understood by those skilled in the art, thereby providing a clearer and more explicit definition of the scope of protection of the present invention.

[0016] Example 1

[0017] The specific preparation method of the detection kit provided by this invention is as follows:

[0018] We established amplification systems for the target regions. For the EYA4 and LCAT genes, we screened two CpG-rich regions from two targets each. For each region, we designed a pair of primers and screened the optimal amplification system using whole-genome methylation quality control materials.

[0019] The amplification reaction system is shown in Table 1-1 below:

[0020] Table 1-1

[0021] Components Specification volume PCR Mix 2× 10μL EYA4 upstream amplification primers 20μM 0.4μl EYA4 downstream amplification primers 20μM 0.4μl EYA4 fluorescent probe 20μM 0.2μl LCAT upstream amplification primers 20μM 0.4μl LCAT downstream amplification primers 20μM 0.4μl LCAT fluorescent probe 20μM 0.2μl upstream amplification primers for internal control 20μM 0.4μl Downstream amplification primers for internal control 20μM 0.4μl Internal control fluorescent probe 20μM 0.2μl Nuclease-free water 2μl DNA 5μl Overall system 20μl

[0022] The upstream and downstream primer sequences for the EYA4 gene, LCAT gene, and internal reference gene are shown in Table 1-2 below:

[0023] Table 1-2

[0024]

[0025] The amplification reaction procedure is shown in Table 1-3 below:

[0026] Table 1-3

[0027]

[0028] Example 2

[0029] To screen a dual-target methylation detection system for gastric cancer, we collected tissue section samples (including cancerous and adjacent tissues) from 36 gastric cancer patients.

[0030] We first obtained DNA from tissue sections using a commercially available kit: the Blood / Cell / Tissue Gene DNA Extraction Kit (Centrifuge Column Type) (Catalog No. YDP304) manufactured by Tiangen Biotech (Beijing) Co., Ltd. After extraction, the extracted DNA underwent methylation treatment. This DNA methylation treatment used a commercially available kit: the EZ DNA Methylation Kit (Catalog No. D5005) manufactured by ZYMO Research. The specific kit transformation procedure was performed according to the kit instructions. The transformed DNA was then detected using methylation PCR.

[0031] After treatment with the methylation kit, the methylated EYA4 or LCAT genes will produce fluorescent signals during the quantitative real-time PCR detection process, while the unmethylated genes will not produce fluorescent signals.

[0032] The results of EYA4 or LCAT gene methylation detection in 36 gastric cancer tissue and adjacent normal tissue sections are shown in Table 2-1 below:

[0033] Table 2-1

[0034]

[0035]

[0036]

[0037] The results above show that the EYA4 and LCAT genes were methylated positive in all 36 gastric cancer tissue samples, but methylated negative in adjacent normal tissue samples. This indicates that the two target genes can effectively detect gastric cancer. The following experiment will use plasma samples to test the sensitivity and specificity of the detection.

[0038] Example 3

[0039] To verify the clinical performance of the dual-gene methylation assay kit, we collected plasma samples from several patients clinically diagnosed with gastric cancer, healthy individuals, patients with benign gastric lesions, and other individuals with gastrointestinal cancers. We then used the EYA4 and LCAT gene dual-gene methylation system for testing and verification.

[0040] The study tested 120 plasma samples from gastric cancer, 158 plasma samples from healthy individuals, 26 plasma samples from colorectal cancer, 32 plasma samples from gastritis, 24 plasma samples from gastric ulcers, 12 plasma samples from liver cancer, and 10 plasma samples from esophageal cancer.

[0041] First, DNA was extracted from the plasma sample. The plasma DNA extraction used a commercially available kit: the Magnetic Bead Serum / Plasma Cell-Free DNA Extraction Kit (catalog number DP709) manufactured by Tiangen Biotech (Beijing) Co., Ltd. After extraction, the extracted DNA underwent methylation treatment. The DNA methylation treatment used a commercially available kit: the EZ DNA Methylation Kit (catalog number D5005) manufactured by ZYMO Research. The specific kit transformation procedure was performed according to the kit instructions. The transformed DNA was then detected by methylation PCR.

[0042] After treatment with the methylation kit, the methylated EYA4 or LCAT genes produced fluorescent signals during quantitative real-time PCR detection, while unmethylated genes did not produce fluorescent signals. The methylation detection results of EYA4 or LCAT genes in all plasma samples are shown in Table 3-1 below:

[0043] Table 3-1

[0044]

[0045]

[0046]

[0047]

[0048]

[0049]

[0050]

[0051]

[0052]

[0053]

[0054]

[0055]

[0056] The optimal positive cutoff value of the kit was determined based on the above data using dual-target combined detection of plasma samples, as follows:

[0057] 1. A CT value ≤ 37 for the LCAT gene indicates LCAT methylation positivity; a CT value > 37 or Unde indicates LCAT methylation negativity.

[0058] 2. An EYA4 gene CT value ≤ 37 indicates EYA4 methylation positivity; a CT value > 37 or Unde indicates EYA4 gene methylation negativity.

[0059] 3. The method for determining the sample test results is shown in Table 3-2 below:

[0060] Table 3-2

[0061]

[0062] Using the above-mentioned positive / negative determination method, 110 out of 120 gastric cancer plasma samples were positive for methylation, with a sensitivity of 91.6%; and 14 out of 262 non-gastric cancer samples were positive for methylation, with a specificity of 94.6%.

[0063] The above description is merely an embodiment of the present invention and does not limit the patent scope of the present invention. Any equivalent structural transformations made based on the content of the present invention specification and drawings, or direct or indirect applications in other related technical fields, are similarly included within the patent protection scope of the present invention.

Claims

1. A composition for detecting methylation of the EYA4 gene and the LCAT gene in human plasma, characterized by: The composition is an EYA4 gene and an LCAT gene.

2. The composition for detecting the methylation of EYA4 gene and LCAT gene in human plasma according to claim 1, characterized in that: The primer sequence of the EYA4 gene is SEQ ID No: 1; and the primer sequence of the LCAT gene is SEQ ID No:

2.

3. The composition for detecting the methylation of EYA4 gene and LCAT gene in human plasma according to claim 2, characterized in that: The probe sequence of the EYA4 gene is SEQ ID No: 4; and the probe sequence of the LCAT gene is SEQ ID No:

5.

4. The composition for detecting the methylation of EYA4 gene and LCAT gene in human plasma according to claim 3, characterized in that: The internal reference for the fluorescence quantitative PCR detection is an ACTB gene, the primer sequence of the ACTB gene is SEQ ID No: 3, and the probe primer sequence is SEQ ID No:

6.

5. A kit for detecting early gastric cancer, characterized by: The composition comprises EYA4 gene primers and probes, LCAT gene primers and probes, ACTB internal reference gene primers and probes, and a PCR amplification enzyme reaction solution.